VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Cancer Res. 2021 05 15; 81(10):2714-2729.
View in:
PubMed
subject areas
Animals
Apoptosis
B7-H1 Antigen
Breast Neoplasms
Cell Proliferation
Colonic Neoplasms
Drug Resistance, Neoplasm
Drug Therapy, Combination
Female
Gene Expression Regulation, Neoplastic
Humans
MAP Kinase Kinase 1
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, Nude
Mice, SCID
Mutation
Myeloid-Derived Suppressor Cells
Poly(ADP-ribose) Polymerase Inhibitors
Protein Kinase Inhibitors
Proto-Oncogene Proteins p21(ras)
Signal Transduction
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
authors with profiles
GORDON B MILLS